BR9606768A - Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra - Google Patents

Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra

Info

Publication number
BR9606768A
BR9606768A BR9606768A BR9606768A BR9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A BR 9606768 A BR9606768 A BR 9606768A
Authority
BR
Brazil
Prior art keywords
valacyclovir hydrochloride
human
treatment
production
viral infection
Prior art date
Application number
BR9606768A
Other languages
English (en)
Portuguese (pt)
Inventor
Barry Howard Carter
Jane Muse Partin
Peter Gregory Varlashkin
Richard Augustus Winnikie
William Bayne Grubb
Gregory Allan Conway
Philip George Lake
David Michael Skinner
David James Whatrup
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10768347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9606768(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of BR9606768A publication Critical patent/BR9606768A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR9606768A 1995-01-20 1996-01-19 Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra BR9606768A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9501178.9A GB9501178D0 (en) 1995-01-20 1995-01-20 Guanine derivative
PCT/GB1996/000117 WO1996022291A1 (en) 1995-01-20 1996-01-19 Guanine derivative

Publications (1)

Publication Number Publication Date
BR9606768A true BR9606768A (pt) 1997-12-30

Family

ID=10768347

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9606768A BR9606768A (pt) 1995-01-20 1996-01-19 Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra

Country Status (40)

Country Link
US (1) US6107302A (OSRAM)
EP (1) EP0804436B1 (OSRAM)
JP (1) JP3176633B2 (OSRAM)
KR (1) KR100376074B1 (OSRAM)
CN (1) CN1049893C (OSRAM)
AP (1) AP662A (OSRAM)
AR (1) AR002270A1 (OSRAM)
AT (1) ATE302777T1 (OSRAM)
AU (1) AU702794B2 (OSRAM)
BG (1) BG63393B1 (OSRAM)
BR (1) BR9606768A (OSRAM)
CA (1) CA2210799C (OSRAM)
CY (1) CY2531B1 (OSRAM)
CZ (1) CZ297065B6 (OSRAM)
DE (1) DE69635106T2 (OSRAM)
DK (1) DK0804436T3 (OSRAM)
EA (1) EA000364B1 (OSRAM)
EE (1) EE03528B1 (OSRAM)
ES (1) ES2248806T3 (OSRAM)
FI (1) FI973063A7 (OSRAM)
GB (1) GB9501178D0 (OSRAM)
GE (1) GEP20001940B (OSRAM)
HR (1) HRP960024B1 (OSRAM)
HU (1) HU222993B1 (OSRAM)
IL (1) IL116831A (OSRAM)
IN (1) IN182468B (OSRAM)
IS (1) IS2268B (OSRAM)
NO (1) NO315558B1 (OSRAM)
NZ (1) NZ298851A (OSRAM)
OA (1) OA10499A (OSRAM)
PL (1) PL182175B1 (OSRAM)
RO (1) RO118693B1 (OSRAM)
RS (1) RS49518B (OSRAM)
SI (1) SI0804436T1 (OSRAM)
SK (1) SK285329B6 (OSRAM)
TR (1) TR199700656T1 (OSRAM)
UA (1) UA46001C2 (OSRAM)
UY (1) UY25779A1 (OSRAM)
WO (1) WO1996022291A1 (OSRAM)
ZA (1) ZA96449B (OSRAM)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
WO1997025989A1 (en) * 1996-01-19 1997-07-24 Glaxo Group Limited Use of valaciclovir for the manufacture of a medicament for the treatment of genital herpes by a single daily application
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
KR20000070223A (ko) * 1997-01-17 2000-11-25 에가시라 구니오 신규한 ｚ-발라사이클로비르 결정
GB0010446D0 (en) * 2000-04-28 2000-06-14 Glaxo Wellcome Kk Pharmaceutical formulation
SK288003B6 (sk) * 2001-02-24 2012-10-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthin derivatives, method for the preparation thereof, pharmaceutical composition containing thereof and their use
CN1551880A (zh) * 2001-09-07 2004-12-01 ������ҩ��ҵ���޹�˾ 阿昔洛韦缬氨酸酯盐酸盐的晶型
EP1453834A1 (en) * 2001-11-05 2004-09-08 Glaxo Group Limited Anhydrous crystal form of valaciclovir hydrochloride
CA2649826A1 (en) * 2001-11-14 2003-05-22 Teva Pharmaceutical Industries Ltd. Synthesis and purification of valacyclovir
EP1517678A2 (en) * 2002-06-24 2005-03-30 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
EP1551838B1 (en) * 2002-10-16 2006-08-09 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US20060229322A1 (en) * 2002-12-09 2006-10-12 Pau Cid Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
EP2014660A3 (en) 2003-06-02 2009-07-15 Teva Pharmaceutical Industries Ltd Novel crystalline forms of valacyclovir hydrochloride
WO2005073233A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
CA2572268A1 (en) * 2004-06-30 2006-02-02 Teva Pharmaceutical Industries Ltd. Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
US20060178512A1 (en) * 2005-02-04 2006-08-10 Cheruthur Govindan Method for preparing amino acid esters of nucleoside analogues
ES2379804T3 (es) * 2005-05-25 2012-05-03 Eli Lilly And Company Ésteres de ciclopropanocarboxilato de aciclovir
EP1746098A1 (en) 2005-07-21 2007-01-24 SOLMAG S.p.A. Valacyclovir polymorphs and a process for the preparation thereof
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process
NZ573360A (en) 2006-05-04 2012-08-31 Boehringer Ingelheim Int Polymorphic forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
CN1903854B (zh) * 2006-08-09 2012-05-23 丽珠医药集团股份有限公司 一种合成盐酸伐昔洛韦的方法
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
GB0710277D0 (en) * 2007-05-30 2007-07-11 Univ Birmingham Use of antivirals in the treatment of medical disorders
MX2010001821A (es) * 2007-08-17 2010-03-10 Boehringer Ingelheim Int Derivados de purina para uso en el tratamiento de enfermedades relacionadas con fap.
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
ES2764251T3 (es) * 2008-08-15 2020-06-02 Boehringer Ingelheim Int Inhibidores de DPP-4 para uso en el tratamiento de curación de heridas en pacientes diabéticos
KR20110067096A (ko) 2008-09-10 2011-06-21 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 및 관련 상태를 치료하기 위한 병용 요법
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EA022310B1 (ru) 2008-12-23 2015-12-30 Бёрингер Ингельхайм Интернациональ Гмбх Солевые формы органического соединения
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
BR112012012641A2 (pt) 2009-11-27 2020-08-11 Boehringer Ingelheim International Gmbh TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
NZ602921A (en) 2010-05-05 2016-01-29 Boehringer Ingelheim Int Combination therapy comprising the administration of a glp-1 receptor agonist and a ddp-4 inhibitor
WO2011158252A1 (en) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Process for the preparation of valacyclovir hydrochloride polymorphic form ii
KR20190050871A (ko) 2010-06-24 2019-05-13 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
CN102584825B (zh) * 2011-01-17 2014-04-02 四川科伦药物研究有限公司 一种合成盐酸伐昔洛韦的方法
CA2841552C (en) 2011-07-15 2020-06-23 Boehringer Ingelheim International Gmbh Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
EP2852592A4 (en) * 2011-11-25 2015-12-23 Piramal Entpr Ltd PROCESS FOR THE PREPARATION OF VALACYCLOVIR CHLORHYDRATE
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
CN110437231B (zh) * 2019-09-04 2022-04-29 上药康丽（常州）药业有限公司 一种盐酸伐昔洛韦无水晶型ⅰ的制备方法
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5831075A (en) * 1993-06-10 1998-11-03 Rolabo Sl Amino acid ester of nucleoside analogues
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative

Also Published As

Publication number Publication date
KR19980701525A (ko) 1998-05-15
SK285329B6 (sk) 2006-11-03
KR100376074B1 (ko) 2003-06-02
EA199700124A1 (ru) 1997-12-30
AU702794B2 (en) 1999-03-04
CN1179159A (zh) 1998-04-15
ZA96449B (en) 1996-08-07
RS49518B (sr) 2006-10-27
HRP960024A2 (en) 1997-10-31
IS4527A (is) 1997-07-15
FI973063L (fi) 1997-09-18
CA2210799C (en) 2008-06-10
IN182468B (OSRAM) 1999-04-17
US6107302A (en) 2000-08-22
CA2210799A1 (en) 1996-07-25
EP0804436A1 (en) 1997-11-05
NZ298851A (en) 1999-01-28
SI0804436T1 (sl) 2006-02-28
EP0804436B1 (en) 2005-08-24
BG63393B1 (bg) 2001-12-29
CN1049893C (zh) 2000-03-01
YU3396A (sh) 1998-12-23
ES2248806T3 (es) 2006-03-16
EA000364B1 (ru) 1999-06-24
HUP9801836A2 (hu) 1999-05-28
DE69635106T2 (de) 2006-06-08
HU222993B1 (hu) 2004-01-28
TR199700656T1 (xx) 1998-03-21
NO315558B1 (no) 2003-09-22
RO118693B1 (ro) 2003-09-30
JP3176633B2 (ja) 2001-06-18
NO973326D0 (no) 1997-07-18
PL182175B1 (pl) 2001-11-30
ATE302777T1 (de) 2005-09-15
HRP960024B1 (en) 2005-08-31
FI973063A7 (fi) 1997-09-18
AU4453996A (en) 1996-08-07
HUP9801836A3 (en) 1999-06-28
OA10499A (en) 2002-04-10
DE69635106D1 (de) 2005-09-29
CY2531B1 (en) 2006-04-12
AP662A (en) 1998-08-19
CZ229497A3 (en) 1997-12-17
UY25779A1 (es) 2000-08-21
GB9501178D0 (en) 1995-03-08
AR002270A1 (es) 1998-03-11
UA46001C2 (uk) 2002-05-15
IL116831A (en) 1998-10-30
EE9700175A (et) 1998-02-16
CZ297065B6 (cs) 2006-08-16
SK96597A3 (en) 1998-02-04
MX9705462A (es) 1997-10-31
GEP20001940B (en) 2000-02-05
JPH11503718A (ja) 1999-03-30
DK0804436T3 (da) 2005-12-27
NO973326L (no) 1997-09-16
WO1996022291A1 (en) 1996-07-25
IL116831A0 (en) 1996-05-14
IS2268B (is) 2007-07-15
BG101833A (bg) 1998-04-30
FI973063A0 (fi) 1997-07-18
PL321326A1 (en) 1997-12-08
AP9701058A0 (en) 1997-10-31
EE03528B1 (et) 2001-10-15

Similar Documents

Publication Publication Date Title
BR9606768A (pt) Cloridreto de valaciclovir uso do mesmo e processo para o tratamento de infecção virótica de herpes em um ser humano e para a produção de cloridreto de valaciclovir na forma cristalina anidra
FI953981A0 (fi) 2-Bentsyyli-polysykliset guaniinijohdannaiset ja menetelmä niiden valmistamiseksi
PT737199E (pt) Processo de preparacao de compostos de silicio biologicamente activos sob a forma concentrada
BR9101203A (pt) Artigo para tratamento de superficie e processo para sua fabricacao
PT92487A (pt) Processo para a preparacao de derivados de peptidos
PT96321A (pt) Processo para a preparacao de nucleosidos de purina
BR9107115A (pt) Processo para a preparacao continua de sulfatos de glicerideos parciais
BR8802677A (pt) Aplicador de medicamento percutaneo e processo de fabricacao do mesmo
BR9406750A (pt) Processo para a fabricaçao de artigo ferramental mestre para replicaçao e artigo obtido
BR9205517A (pt) Processo para a preparacao continua de mosto e processo para preparar cerveja
BR9708533A (pt) Limitado retrorreflexivo artigo e processo para produzir um limitado retrorreflexivo
BR8803368A (pt) Processo para fabricar paredes laterais de lata em forma de troncos piramidas e equipamento para executar o processo
BR8903681A (pt) Processo para fabricar um artigo de limpeza e respectivo artigo de limpeza
BR9402087A (pt) Processo para a produção de isocianatos puros e utilização
BR9004421A (pt) Composicoes anti-estaticas e amaciantes de tecidos e processo para amaciar e prover um acabamento anti-estatico a tecidos
BR9406737A (pt) Instrumento cirúrgico a processo para remover tumores neurológicos
BR8800841A (pt) Laminador de cilindros axialmente deslocaveis e processo de regulagem de perfil de cilindro axialmente deslocaveis em um laminador
BR9303876A (pt) Processo para a preparacao de pirrol-(2,3-d)-pirimidinas substituidas na posicao 5 e composto obtido
BR9303403A (pt) Processo para produzir um artigo de borracha e artigo de borracha
BR9005438A (pt) Poliaminas e seu processo de preparacao
BR9507494A (pt) Processo para a preparação de famciclovi de 2-amino-6-cloro purina e processo para a preparação de penciclovi de 2-amino-6- cloro purina
EE9600020A (et) 9-asendatud 2-(2-n-alkoksüfenüül)puriin-6-oonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
BR8806375A (pt) Processo para produzir fluoreto de titanio
PT89809A (pt) Processo para a preparacao de pirimidinas substituidas
AU6748090A (en) Use of caffeine in the treatment of herpes simplex virus infections

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
HJEG Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law
FF Decision: intention to grant
FG9A Patent or certificate of addition granted
B17A Notification of administrative nullity (patentee has 60 days time to reply to this notification)

Free format text: NATURE S PLUS FARMACEUTICA LTDA.